Adverse Reactions to First-Line Anti-Tuberculosis Drugs As a Risk Factor of Pulmonary Tuberculosis Treatment

First-line drugs for tuberculosis (TB) still need to be used to treat pulmonary TB. Bad drug reactions (ADRs), on the other hand, make it hard to stay on treatment, which can lead to less-than-ideal results and the spread of TB that drugs can't stop. ADRs can happen with first-line drugs used to treat TB. This review talks about these issues and how they make it tough for people to keep up with their treatment. It also gives ideas for how to make these issues less important.

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2025-04-17
DOI
https://doi.org/10.5281/zenodo.15236307
Primary Topic
Tuberculosis Research and Epidemiology
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Adverse Reactions to First-Line Anti-Tuberculosis Drugs As a Risk Factor of Pulmonary Tuberculosis Treatment

Zenodo (CERN European Organization for Nuclear Research)
Tuberculosis Research and Epidemiology
article

Adverse Reactions to First-Line Anti-Tuberculosis Drugs As a Risk Factor of Pulmonary Tuberculosis Treatment

article en

Abstract

First-line drugs for tuberculosis (TB) still need to be used to treat pulmonary TB. Bad drug reactions (ADRs), on the other hand, make it hard to stay on treatment, which can lead to less-than-ideal results and the spread of TB that drugs can't stop. ADRs can happen with first-line drugs used to treat TB. This review talks about these issues and how they make it tough for people to keep up with their treatment. It also gives ideas for how to make these issues less important.

Zenodo (CERN European Organization for Nuclear Research)
Good health and well-being
Openalex Percentile: Top 50%
Tuberculosis Research and Epidemiology
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Adverse Reactions to First-Line Anti-Tuberculosis Drugs As a Risk Factor of Pulmonary Tuberculosis Treatment · Zenodo (CERN European Organization for Nuclear Research) (2025) | TGRS Research Map | TGRS